Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

NCT06490328

Status	RECRUITING
Phase	Phase 3
Sponsor	Dongkook Pharmaceutical Co., Ltd.
Enrollment	154 participants

Plain Language Summary

This study is testing a new drug called DKF-MA102 in men with prostate cancer. The study aims to evaluate how safe the drug is and how well it works as a treatment, particularly in men who still have active testosterone levels.

You may be eligible if...
- You are a male aged 19 or older with a confirmed prostate cancer diagnosis
- Your testosterone level is above 150 ng/dL (meaning you have not had full hormone suppression)
- Your overall health is adequate (ECOG 0–2)
- Your expected survival is at least 1 year

You may NOT be eligible if...
- You have had prior treatment that would interfere with this drug
- You have significant heart, liver, or kidney problems
- You have active serious infections

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (5)

- Adult male aged 19 or older
- Histologically or cytologically-confirmed prostate cancer
- Serum testosterone level \>150 ng/dL
- ECOG PS grade d 2
- Life expectancy of at least 1 year

Exclusion (22)

- History of surgical procedures such as testicular resection, adrenal resection, and pituitary resection
- History of hormone therapy
- History of 5±reductase inhibitor
- History of radical radiation therapy
- History of adjuvant male hormone block therapy

... and 17 more (see full listing online)

Locations (1 total)

Ewha Womans University mokdong Hospital, Seoul, South Korea

---

https://clinicaltrials.gov/study/NCT06490328